Aclaris Therapeutics Inc
Company Profile
Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Contact
701 Lee Road
Suite 103
WaynePA19087
USAT: +1 484 324-7933
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
64
Stocks News & Analysis
stocks
Cutting our fair value on ASX share after poor guidance
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,868.20 | 33.10 | -0.37% |
| CAC 40 | 8,030.33 | 22.18 | -0.28% |
| DAX 40 | 24,084.22 | 78.43 | -0.32% |
| Dow JONES (US) | 47,560.29 | 179.03 | -0.38% |
| FTSE 100 | 9,648.59 | 6.58 | 0.07% |
| HKSE | 25,540.78 | 106.55 | 0.42% |
| NASDAQ | 23,576.49 | 30.58 | 0.13% |
| Nikkei 225 | 50,602.80 | 52.30 | -0.10% |
| NZX 50 Index | 13,371.06 | 83.72 | -0.62% |
| S&P 500 | 6,840.51 | 6.00 | -0.09% |
| S&P/ASX 200 | 8,579.40 | 31.70 | -0.37% |
| SSE Composite Index | 3,900.50 | 9.03 | -0.23% |